Q-omics provides the consensus-scored KRT128P profile across patient tissues and cancer cell-line models. KRT128P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, KRT128P is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, KRT128P RNA expression shows 6,385 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight UCS, PRAD, and COAD as cancer lineages where KRT128P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT128P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT128P survival associations across molecular data types. KRT128P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT128P RNA expression–survival associations across cancer types. High KRT128P expression shows unfavorable associations in UCS, READ, THYM, SKCM, BLCA and STAD. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for KRT128P RNA expression.
This table summarizes KRT128P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT128P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT128P shows higher tumor expression in PRAD. The PRAD box plot shows higher KRT128P RNA expression in tumor versus normal tissue (log2 FC = +0.013, t-test p = .011).
This table shows molecular features associated with KRT128P in patient tissues and cancer cell lines. In patient samples, KRT128P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
